The purpose of the Medication Competition Act is to streamline the process for determining how long licensed biological products can enjoy exclusivity, meaning the period during which they are protected from competition. This act aims to enhance market competition by ensuring that information about exclusivity periods is made available more quickly, which can help bring lower-cost alternatives to market sooner. Key provisions of the act require the Secretary of Health and Human Services to determine and publish the exclusivity periods for biological products.